CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
gemcitabine hydrochloride +1 moredrug
Likely dose
gemcitabine hydrochloride 750 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00577889
NCT00577889Phase 2Completed
CompareCT.gov

A Phase II Trial of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

National Cancer Institute (NCI)·interventional·Posted Dec 20, 2007·Updated Jul 25, 2014

In Brief

A Phase 2 clinical trial evaluating gemcitabine hydrochloride and tanespimycin for Adenocarcinoma of the Pancreas and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This randomized phase II trial is studying three different schedules of gemcitabine hydrochloride and tanespimycin to see how well they work in treating patients with stage IV pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and tanespimycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2007
Enrollment StartMar 1, 2008
Primary CompletionJan 1, 2011
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.5 years ago

Interventions

gemcitabine hydrochloridedrug

750 mg/m2 Given IV

tanespimycindrug

154 mg/m2 Given IV